Neurological Surgery 脳神経外科49巻3号

2021年05月発行

特集 グリオーマ—現在の常識と近未来のスタンダード Ⅴ各種グリオーマの集学的治療戦略

膠芽腫

著者： 田中將太¹

所属機関： ¹東京大学医学部脳神経外科

ページ範囲：P.623 - P.631

Point
・膠芽腫に対し，外科的摘出，放射線療法，化学療法による集学的治療が重要である．
・腫瘍治療電場を利用したNovoTTF（オプチューン^®）が，初発膠芽腫の新規治療として認可された．
・症候性てんかんには，薬剤相互作用の少ない新規抗てんかん薬が選択されることが多い．

参考文献

1）Ostrom QT, et al：CBTRUS statistical report：primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 22（12 Suppl 2）：iv1-iv96, 2020

2）Stupp R, et al；European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups；National Cancer Institute of Canada Clinical Trials Group：Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352：987-996, 2005

3）Stupp R, et al；European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups；National Cancer Institute of Canada Clinical Trials Group：Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study：5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10：459-466, 2009

4）Stupp R, et al：Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma：a randomized clinical trial. JAMA 318：2306-2316, 2017

5）Reardon DA, et al：Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma：the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6：1003-1010, 2020

6）Vuorinen V, et al：Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir（Wien）145：5-10, 2003

7）Lacroix M, et al：A multivariate analysis of 416 patients with glioblastoma multiforme：prognosis, extent of resection, and survival. J Neurosurg 95：190-198, 2001

8）Stummer W, et al；ALA-Glioma Study Group：Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma：a randomised controlled multicentre phase Ⅲ trial. Lancet Oncol 7：392-401, 2006

9）Sanai N, et al：An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115：3-8, 2011

10）Brown TJ, et al：Association of the extent of resection with survival in glioblastoma：a systematic review and meta-analysis. JAMA Oncol 2：1460-1469, 2016

11）Marko NF, et al：Extent of resection of glioblastoma revisited：personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol 32：774-782, 2014

12）Ellingson BM, et al：Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol 20：1240-1250, 2018

13）Kreth FW, et al；German Glioma Network：Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 24：3117-3123, 2013

14）Wen PY, et al：Glioblastoma in adults：a Society for Neuro-Oncology（SNO）and European Society of Neuro-Oncology（EANO）consensus review on current management and future directions. Neuro Oncol 22：1073-1113, 2020

15）McGirt MJ, et al：Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65：463-469；discussion 469-470, 2009

16）Hochberg FH, Pruitt A：Assumptions in the radiotherapy of glioblastoma. Neurology 30：907-911, 1980

17）Chang CH, et al：Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52：997-1007, 1983

18）Roa W, et al：Abbreviated course of radiation therapy in older patients with glioblastoma multiforme：a prospective randomized clinical trial. J Clin Oncol 22：1583-1588, 2004

19）Roa W, et al：International Atomic Energy Agency randomized phase Ⅲ study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 33：4145-4150, 2015

20）Hermanto U, et al：Intensity-modulated radiotherapy（IMRT）and conventional three-dimensional conformal radiotherapy for high-grade gliomas：does IMRT increase the integral dose to normal brain? Int J Radiat Oncol Biol Phys 67：1135-1144, 2007

21）Amelio D, et al：Intensity-modulated radiation therapy in newly diagnosed glioblastoma：a systematic review on clinical and technical issues. Radiother Oncol 97：361-369, 2010

22）Balana C, et al：A phase Ⅱ randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma（GEINO 14-01）. Neuro Oncol 22：1851-1861, 2020

23）Blumenthal DT, et al：Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma：a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol 19：1119-1126, 2017

24）Hegi ME, et al：MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352：997-1003, 2005

25）Esteller M, et al：Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343：1350-1354, 2000

26）Gilbert MR, et al：Dose-dense temozolomide for newly diagnosed glioblastoma：a randomized phase Ⅲ clinical trial. J Clin Oncol 31：4085-4091, 2013

27）Tanaka S, et al：Diagnostic and therapeutic avenues for glioblastoma：no longer a dead end? Nat Rev Clin Oncol 10：14-26, 2013

28）Chinot OL, et al：Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370：709-722, 2014

29）Gilbert MR, et al：A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370：699-708, 2014

30）Friedman HS, et al：Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27：4733-4740, 2009

31）Wick W, et al：Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377：1954-1963, 2017

32）Westphal M, et al：A phase 3 trial of local chemotherapy with biodegradable carmustine（BCNU）wafers（Gliadel wafers）in patients with primary malignant glioma. Neuro Oncol 5：79-88, 2003

33）Wakabayashi T, et al；Members of Japan Clinical Oncology Group Brain Tumor Study Group（JCOG-BTSG）：JCOG0911 INTEGRA study：a randomized screening phase Ⅱ trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol 138：627-636, 2018

system for glioblastoma：The Patient Registry Dataset（PRiDe）. Semin Oncol 41 Suppl 6：S4-S13, 2014

35）Muragaki Y, et al：Phase Ⅱ clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg 119：845-852, 2013

36）van Breemen MS, et al：Epilepsy in patients with brain tumours：epidemiology, mechanisms, and management. Lancet Neurol 6：421-430, 2007

37）Wu AS, et al：A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg 118：873-883, 2013

38）Greenhalgh J, et al：Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Cochrane Database Syst Rev 4：CD007286, 2020

39）Göttlicher M, et al：Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20：6969-6978, 2001

40）Bobustuc GC, et al：Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12：917-927, 2010

41）Happold C, et al：Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 34：731-739, 2016

-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8：971-978, 2002

43）Lange F, et al：AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. PLoS One 14：e0211644, 2019

44）Grossman SA, et al：Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma：a multicenter phase Ⅱ trial. J Clin Oncol 27：4155-4161, 2009

45）Venkatesh HS, et al：Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161：803-816, 2015

46）Venkatesh HS, et al：Electrical and synaptic integration of glioma into neural circuits. Nature 573（7775）：539-545, 2019

47）Collins FS, Varmus H：A new initiative on precision medicine. N Engl J Med 372：793-795, 2015

48）Chi AS, et al：Exploring predictors of response to dacomitinib in EGFR-amplified recurrent glioblastoma. JCO Precis Oncol 4：PO.19.00295, 2020

49）Patel AP, et al：Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344（6190）：1396-1401, 2014

50）Louis DN, et al：cIMPACT-NOW update 6：new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30：844-856, 2020

51）Konteatis Z, et al：Vorasidenib（AG-881）：a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett 11：101-107, 2020

52）Machida Y, et al：A potent blood-brain barrier-permeable mutant IDH1 inhibitor suppresses the growth of glioblastoma with IDH1 mutation in a patient-derived orthotopic xenograft model. Mol Cancer Ther 19：375-383, 2020

53）Johnson DR, O'Neill BP：Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107：359-364, 2012

54）Johnson DR, et al：Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab：a population-based analysis. Cancer 119：3489-3495, 2013